Pure Global AI
Manufacturer profile

FRESENIUS HEMOCARE BRASIL LTDA.

BrazilBrazil26 ANVISA registrations14 unique technical categoriesJul 18, 1996 – Jun 13, 2022
Verified
26
Total products
14
Technical names
Jul 1996
Earliest registration
Jun 2022
Latest registration
Regulatory footprint
Search FRESENIUS HEMOCARE BRASIL LTDA. across other regulatory registries
ThailandEuropean UnionColombiaSouth KoreaCanadaEcuador
Recent registrations
Latest 5 products registered by this manufacturer
Leukocyte Removal Filter (Transfusion)
BioR flex - filtros para remoção de leucócitos (beira leito)
Class III · Jun 13, 2022
ANTI-HUMAN GLOBULIN (COOMBS)
Soro de Coombs
Class III · Nov 27, 2017
COMBINED PARAMETERS IN THE SAME PRODUCT - CLASS IV
CONTROL KIT
Class IV · Feb 22, 2011
Shaker and Homogenizer
COMPOGUARD
Class I · Feb 17, 2010
Tube Sealer
HEMOSEAL HD
Class I · Dec 07, 2009
Most popular products
Products with most registrations
Blood Bags
6 registrations
Leukocyte Removal Filter (Transfusion)
3 registrations
Shaker and Homogenizer
3 registrations
Tube Sealer
3 registrations
Filter For Leukocyte Removal (Laboratory)
2 registrations
Top registration holders
Companies holding product registrations for this manufacturer
FRESENIUS HEMOCARE BRASIL LTDA.
25 products
Top competitors
Companies with the most overlapping products (same technical names)
MEDION GRIFOLS DIAGNOSTICS AG
Switzerland
31 registrations6 shared products
Shared products
ANTI-HUMAN GLOBULIN (COOMBS), COMBINED PARAMETERS IN THE SAME PRODUCT - CLASS IV, IMMUNOHEMATOLOGY - LECTINS, IMMUNOHEMATOLOGY - RARE SERA FOR CONVENTIONAL METHODOLOGY, IMMUNOHEMATOLOGY - RED BLOOD CELL REAGENTS/ENZYME-TREATED RED BLOOD CELL REAGENTS, IMMUNOHEMATOLOGY - RH-HR, KELL, KIDD, DUFFY - MONOCLONAL ORIGIN
DIAMED GMBH
Switzerland
12 registrations6 shared products
Shared products
ANTI-HUMAN GLOBULIN (COOMBS), COMBINED PARAMETERS IN THE SAME PRODUCT - CLASS IV, IMMUNOHEMATOLOGY - COMPLEMENTARY REAGENTS, IMMUNOHEMATOLOGY - RH-HR, KELL, KIDD, DUFFY - MONOCLONAL ORIGIN, IMUNOHEMATOLOGIA - REAGENTES COMPLEMENTARES, IMUNOHEMATOLOGIA - RH-HR, KELL, KIDD, DUFFY - ORIGEM MONOCLONAL
SCAN DIAGNÓSTICA INDÚSTRIA E COMÉRCIO LTDA
Brazil
9 registrations6 shared products
Shared products
ANTI-HUMAN GLOBULIN (COOMBS), COMBINED PARAMETERS IN THE SAME PRODUCT - CLASS IV, IMMUNOHEMATOLOGY - COMPLEMENTARY REAGENTS, IMMUNOHEMATOLOGY - RED BLOOD CELL REAGENTS/ENZYME-TREATED RED BLOOD CELL REAGENTS, IMMUNOHEMATOLOGY - RH-HR, KELL, KIDD, DUFFY - MONOCLONAL ORIGIN, TIPAGEM SANGUÍNEA MÚLTIPLA ABO - ORIGEM MONOCLONAL
LORNE LABORATORIES LTD
United Kingdom
6 registrations6 shared products
Shared products
ANTI-HUMAN GLOBULIN (COOMBS), IMMUNOHEMATOLOGY - COMPLEMENTARY REAGENTS, IMMUNOHEMATOLOGY - LECTINS, IMMUNOHEMATOLOGY - RARE SERA FOR CONVENTIONAL METHODOLOGY, IMMUNOHEMATOLOGY - RH-HR, KELL, KIDD, DUFFY - MONOCLONAL ORIGIN, TIPAGEM SANGUÍNEA MÚLTIPLA ABO - ORIGEM MONOCLONAL
DIAGNOSTIC GRIFOLS, S.A.
Spain
11 registrations5 shared products
Shared products
ANTI-HUMAN GLOBULIN (COOMBS), IMMUNOHEMATOLOGY - COMPLEMENTARY REAGENTS, IMMUNOHEMATOLOGY - RARE SERA FOR CONVENTIONAL METHODOLOGY, IMMUNOHEMATOLOGY - RH-HR, KELL, KIDD, DUFFY - MONOCLONAL ORIGIN, IMUNOHEMATOLOGIA - SOROS RAROS PARA METODOLOGIA CONVENCIONAL
About this profile

Explore comprehensive manufacturer profile for FRESENIUS HEMOCARE BRASIL LTDA. based in Brazil through Pure Global AI's free Brazil medical device database. This manufacturer has 26 products registered with ANVISA across 14 unique technical categories. Their regulatory history spans from Jul 18, 1996 to Jun 13, 2022.

This page provides detailed insights including 5 recent product registrations including Leukocyte Removal Filter (Transfusion), 5 most popular products with Blood Bags having 6 registrations, 1 registration holders including FRESENIUS HEMOCARE BRASIL LTDA., and 5 key competitors with MEDION GRIFOLS DIAGNOSTICS AG sharing 6 products. Pure Global AI offers free access to over 100,000+ Brazilian medical device registrations, enabling global MedTech companies to analyze market dynamics and identify opportunities.